Contrast-enhanced Ultrasound in Children

Article

Cost and safety of using contrast-enhanced ultrasound for children.

Pediatric contrast-enhanced ultrasound (CEUS) is a safe procedure and allows for less ionizing radiation and gadolinium contrast administration, according to a study in the American Journal of Roentgenology.

Researchers from the United Kingdom analyzed adverse incidents encountered in pediatric CEUS, and sought to determine if there were financial benefits to reducing the number of CT and MRI examinations among children.

The researchers analyzed all CEUS examinations performed on children aged 18 and younger between January 2008 and December 2015. The children received a median dose of 2.4 mL of a sulfur hexafluoride microbubble contrast agent, with ranges from 0.1 mL to 4.8 mL. All immediate reactions deemed due to contrast examinations were documented in radiology reports. Electronic patient records were examined for adverse reactions within 24 hours not due to an underlying pathologic condition. Costs were also compared: CEUS utilization cost at $94, CT at $168, and MRI at $274.

The results showed that of 187 boys and 118 girls (305 children total), 147 studies (48.2%) were ordered to characterize liver lesions and 113 studies (37.1%) for trauma. The remaining 45 studies (14.8%) were for renal, vascular, and intracavitary assessment. There were no immediate adverse reactions and delayed adverse reactions occurred in two patients (0.7%): transient hypertension and transient tachycardia. Neither was symptomatic, and both were deemed not due to the underlying disorder. The potential cost savings of CEUS was $74 per examination over CT and $180 over MRI.

The researchers concluded that the use of pediatric CEUS is safe and potentially cost-effective. Using CEUS in this population allows reduction in the ionizing radiation associated with CT and in the gadolinium contrast administration, sedation, and anesthesia sometimes required for MRI.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.